Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 11/20 | 0.44 |
| ▸ | DRD3 | P35462 | 11/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212534 | 0.85 | L3MBTL1 (0.50) | DRD2SLC6A4HTR1AHTR2ADRD3 | |
| SCHEMBL6215166 | 0.83 | MAOB (0.53) | DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL5564087 | 0.83 | DRD2 (0.50) | DRD2SLC6A4HTR1AHTR2ADRD3 | |
| SCHEMBL6296077 | 0.83 | DRD2 (0.47) | DRD2SLC6A4HTR1AHTR2ADRD3 | |
| SCHEMBL18872185 | 0.81 | HTR1A (0.53) | DRD2SLC6A4HTR1ADRD3SIGMAR1 | |
| SCHEMBL6214207 | 0.81 | HTR1A (0.48) | DRD2SLC6A4HTR1AHTR2ADRD3 | |
| SCHEMBL5567706 | 0.79 | KCNA3 (0.54) | DRD2HTR2ADRD3 | |
| SCHEMBL6296111 | 0.79 | DRD2 (0.43) | DRD2SLC6A4HTR1AHTR2ADRD3 | |
| SCHEMBL5345674 | 0.78 | DRD2 (0.51) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL6642667 | 0.78 | SIGMAR1 (0.44) | DRD2HTR1AHTR2ADRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122254-B1 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| EP-1122254-A2 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | DRD2 125/4885SLC6A4 918/4885HTR1A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.